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Background: Bone-targeting agents (BTAs), such as bisphosphonates and denosumab, have demonstrated
no discernable effects on tumour response or disease free/overall survival in patients with bone me-
tastases from breast cancer. Doxycycline is both osteotropic and has anti-cancer effects. When combined
with zoledronate in animal models, doxycycline showed signiﬁcantly increased inhibition of tumour
burden and increased bone formation. We evaluated the effects of adding doxycycline to ongoing anti-
cancer therapy in patients with metastatic breast cancer.
Methods: Breast cancer patients with bone metastases and Z3 months of BTA use, entered this single-
arm study. Patients received doxycycline 100 mg orally, twice a day for 12 weeks. The co-primary end-
points were; effect on validated pain scores (FACT-Bone pain and Brief Pain Inventory) and bone re-
sorption markers (serum C-telopeptide, [sCTx]). All endpoints (pain scores, sCTx, bone-speciﬁc alkaline
phosphatase, skeletal-related events, toxicity) were evaluated at baseline, 4, 8 and 12 weeks. Bone
marrow was sampled at baseline and week 12 for exploratory biomarker analysis.
Results: Out of 37 enroled patients, 27 (73%) completed 12 weeks of therapy. No signiﬁcant changes were
seen in pain scores or bone turnover markers. Failure to complete treatment: drug toxicity (70%) and
disease progression (30%). Sixteen (43%) patients had GI adverse events.
Conclusions: Doxycycline 100 mg twice daily for 12 weeks had no signiﬁcant effects on either bone pain
or bone turnover markers. Its toxicity proﬁle in this patient population would make further evaluation
challenging.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Translational relevance
This is the largest study to date evaluating the effects of dox-
ycycline in bone-metastatic breast cancer patients. Doxycycline
daily for 12 weeks did not appear to signiﬁcantly enhance pallia-
tive beneﬁt nor change bone resorption markers. The toxicityGmbH. This is an open access art
cology, The Ottawa Hospital
y of Ottawa, Ottawa, Ontario,
).proﬁle of doxycycline in metastatic breast cancer patients will
make further evaluation challenging.1. Background
The biological behaviour of bone metastases causes an un-
coupling of the actions of osteoclastic and osteoblastic cells, re-
sulting in increased in bone turnover [1]. In clinical practice the
main mechanism of action of bone-targeting agents (BTAs) (e.g.
bisphosphonates or denosumab) has been through osteoclast in-
hibition [1,2] with resulting reduction in skeletal-related events
(SREs) [3]. Despite numerous studies reporting direct anti-tumouricle under the CC BY-NC-ND license
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models, large randomized placebo-controlled trials in patients
with metastatic breast cancer have shown no evidence of im-
provement in terms of response rate, progression free or overall
survival [4,5]. One strategy to enhance the direct anti-tumour
activities of BTAs in the metastatic and adjuvant settings might
involve the addition of the widely available, safe, and inexpensive
drug, doxycycline.
Doxycycline, a tetracycline analogue, is osteotropic with a high
afﬁnity for mineralised bone. In experimental systems, it has de-
monstrated anti-cancer effects including inhibition of matrix me-
talloproteinases, anti-angiogenesis and cytostatic effects on cancer
cells [6]. Preclinical bone metastasis models have shown that
doxycycline could directly inhibit tumour growth, induce bone
reformation [7] as well as increase inhibition of tumour burden
and increase bone formation when combined with zoledronate
[8]. In addition to preclinical data, doxycycline has also undergone
evaluation as an anti-cancer agent in Phase 1 trials and in breast
cancer patients with newly diagnosed bone metastases prior to
commencement of bisphosphonate therapy [9]. These studies
suggest that the addition of doxycycline to a bisphosphonate re-
gimen in breast cancer patients may work synergistically to en-
hance the direct anti-tumour effects and potentially result in in-
creased patient beneﬁt.
We initiated a phase II, single-arm study, where we hypothe-
sised that in women with bone metastases from breast cancer, the
addition of doxycycline to their standard BTA therapy would result
in signiﬁcant palliative beneﬁts as a result of inhibition of tumour
progression and osteolysis. Through the prospective collection of
serum, urine and bone marrow samples, putative mechanisms of
action would be explored.2. Materials and methods
2.1. Objectives
This study was designed to evaluate the effect of adding dox-
ycycline 100 mg orally twice a day for 12 weeks to ongoing anti-
cancer therapy in women with breast cancer and bone metastases.
The primary objective was to explore the potential palliative
beneﬁt of doxycycline in this population. Secondary study objec-
tives included: effects on bone turnover markers, potential asso-
ciations between bone resorption/formation markers, apoptosis
and proliferation with palliative or anti-tumour response, and the
ability to complete therapy, including toxicity and safety.
2.2. Study population
Patients with metastatic breast cancer with radiologically and/
or biopsy conﬁrmed bone metastases who had received Z3
months of BTA therapy (e.g. bisphosphonate or denosumab) were
enroled. Patients had to have an ECOG r2, a life expectancy 43
months and no changes in systemic anti-cancer therapy for
4 weeks prior to study entry or anticipated changes in the 4 weeks
after entering the study. The study was approved by the Ottawa
Health Science Network Research Ethics Board and registered with
clinicaltrials.gov [10].
2.3. Trial design
All study participants received doxycycline 100 mg orally twice
a day for 12 weeks. Participants were provided with a paper diary
to record their compliance with doxycycline. Data on self-reported
bone pain was measured using 2 validated questionnaires: the
Brief Pain Inventory (BPI)-worst pain score [11,12] and FunctionalAssessment of Cancer Therapy-Bone Pain (FACT-BP) [13,14]. Pain,
analgesic use, toxicity, and occurrence of SREs (deﬁned as radio-
therapy or surgery to the bone, pathological fractures, spinal cord
compression, or hypercalcemia) were assessed at baseline and
weeks 4, 8 and 12. Baseline fasting serum c-telopeptide (CTX, a
collagen fragment released as a result of tumour-induced bone
degradation, and hence a surrogate marker of tumour-induced
osteolysis), bone speciﬁc alkaline phosphatase (BSAP), parathyroid
hormone (PTH) and vitamin D (25-OH-vit D) were also measured.
Serum CTx and BSAP were assessed at weeks 4, 8 and 12. At
baseline and week 12, bone marrow aspirate and trephine biopsy
were performed from the posterior iliac crest. If tumour cells were
present in the bone marrow specimen, ER, PR (by im-
munohistochemistry) and Her2 analysis (by FISH) and a marker of
proliferation (Ki67) were measured. Patients could also optionally
consent to the collection of plasma, serum and urine samples
(baseline, weeks 4, 8 and 12) for future translational research
studies.
All patients were advised to take calcium (1200–1500 mg/day)
and vitamin D3 (800–1000 IU/day) while on study. Given that this
study is pragmatic, all other assessments (e.g. scans, blood work)
were at the treating physician's discretion.
2.4. Laboratory analysis
Blood was drawn in the morning following an overnight fast
[15,16]. Samples were allowed to clot and were centrifuged at 4 °C
for 10 min at 3400 RPM. Urine was collected as a second pass,
fasting specimen. Both were frozen at 80 °C until analysis. Ser-
um CTx, BSAP, 25-hydroxyvitamin D and PTH were measured by
chemiluminescence immunoassay: CTx using CrossLaps
s
on an
IDS iSYS automated analyzer, BSAP using Ostase
s
, on the Beckman
Coulter Unicel DxI and 25-OH-VitD on the IDS iSYS and PTH on the
Beckman Coulter Unicel DxI..
All Immunohistochemistry (IHC) testing was done on the Leica-
Bond Platform. IHC for Oestrogen receptor was done using the
6F11 clone (Leica) at 1/150 with Heat Induced Epitope Retrieval
(HIER) in Bond epitope retrieval solution-1 (citrate buffer, pH 6.0).
IHC for Progesterone receptor was done using the PR clone 16
(Bond ready to use) with HIER in Bond epitope retrieval solution-2
(EDTA, pH 9.0). IHC for Ki67 scoring was done using the MIB-1
clone (DAKO) at 1/75 with HIER in Bond epitope retrieval solution-
2. ER and PR positive is deﬁned according to ASCO guidelines as
Z1%. Ki67 score was expressed as a percentage of cells positive
(all cells available counted).
2.5. Statistical analysis
The co-primary endpoints for this study was palliative pain
response at 3 months, based on the BPI questionnaire (BPI-worst),
analgesic use, FACT-BP score and bone resorption markers. As with
previous studies in this patient population, [17,18] complete re-
sponse for palliative pain response was deﬁned as a pain score of
zero at the index site with no concomitant increase in analgesic
intake (stable or reducing analgesics in daily oral morphine
equivalents). Partial response was deﬁned as either a pain reduc-
tion of 2 or more at the index site on 0–10 scale without analgesic
increase, or analgesic reduction of 25% or more from baseline
without an increase in pain. Pain progression was deﬁned as an
increase in pain score of 2 or more points above baseline at the
index site with stable analgesic use or an increase of 25% or more
in daily oral morphine equivalent compared with baseline, with
pain score stable or 1 point above baseline. Pain response was also
evaluated using the FACT-BP. Pain decrease was measured as a 10%
decline compared to baseline, and pain progression was deﬁned as
a 10% increase in the FACT-BP compared to baseline.
Fig. 1. CONSORT diagram.
Table 1
Baseline characteristics.
All patients Missing
number
N 37
Age Median
(range)
60 (42, 88) 0
Duration of bone metastases
(n¼x), months
Median
(range)
13 (4, 94) 0
PTH Median
(range)
5 (1.7, 18.3) 0
Vitamin D Median
(range)
91 (48, 185) 0
Months, taking bisphosphonates
prior to starting study
Median
(range)
10.23 (3.1,
67.8)
0
Baseline CTx Median
(range)
140 (30,
700)
0
Baseline BSAP (n¼x) Median 9.2 (4.4, 0
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decreases in CTx were previously observed to correlate with re-
duction in bone pain [15,16,19,20]. Change was calculated as (on-
study CTx – baseline CTx)/baseline CTx*100%.
Summary statistics were used to describe baseline character-
istics and outcomes. Change from baseline for outcomes at dif-
ferent time points was calculated as (on-study value – baseline
value) and tested using the Wilcoxon rank sum test or t-test as
appropriate. Logistic regression analyses were used to evaluate
baseline characteristics for potential prognostic ability for com-
pletion of study therapy and their prognostic ability of the pa-
tients' response on BPI-worst at week 12. Stepwise selection
(forward) process was used to construct a multivariable model of
prognostic factors. A p-value¼0.20 was chosen as the entry cri-
teria for building the multivariable model, which allowed for more
factors to enter into the model but could result in some over-ﬁt-
ting of the data, to ensure all potentially prognostic factors were
included. The categories of adverse events were chosen on the
basis of the anticipated pharmacological proﬁles of doxycycline
and are summarised by AE grade for each patient. Some variables
were grouped for statistical power purposes. All tests were two-
sided, a p-value of 0.05 or less was considered statistically sig-
niﬁcant and all analyses performed in SAS version 9.2 (SAS In-
stitute, Cary, NC, USA).
2.6. Sample size
As with previous studies, a two-point reduction in the BPI score
from baseline to week 12 was considered a pain response, thus, a
two-point reduction was considered to be clinically important. The
estimated standard deviation of the change in BPI was 4 (ap-
proximately one-quarter of the potential range), therefore, a two-
sided, α¼0.05, one-sample t-test would achieve 480% statistical
power, with a total of 34 patients (NCSS-PASS version 8.0.15).
Further, this sample size would attain 490% statistical power to
detect an effect size of 0.5 or greater in the change in CTx from
baseline and in the change in FACT-BP. Assuming a modest 10%
drop out rate from previous trials of this nature [20–22], the tar-
geted sample size was therefore set to 37 patients.(range) 39.3)
FACT-BP subscale Mean (sd) 46.64
(12.90)
3
BPI-severity (n¼x) Median
(range)
4
Worst pain in last 3 days 2 (0, 9)
Average pain in last 3 days 1 (0, 7)
Pain right Now 0 (0, 8)
Pain interfered with activities 3 (0, 23)
Total number of SRE prior to
study entry
0 17 (45.9%) 0
1 3 (8.1%)
2 3 (8.1%)
3 3 (8.1%)
4 5 (13.5%)
Z5 6 (16.2%)
BPI¼Brief pain inventory; BSAP¼Bone speciﬁc alkaline phosphatase; CTx¼serum
C-telopeptide.3. Results
3.1. Patient enrolment and baseline characteristics
From April 2013 to May 2015, 55 patients were approached to
enter this study, of which 37 patients consented and enroled
(Fig. 1). Baseline patient characteristics are shown in Table 1. The
median age was 60 (range 42–88), the median duration of bone
metastases was 13 months (range 4–94) and median use of prior
IV pamidronate was for 10.2 months (range 3.1–67.8) at baseline.
At the time of study entry the anti-cancer therapy the patients
were receiving were; endocrine therapy (20 patients), che-
motherapy (15 patients) and chemotherapy with trastuzumab (2
patients).
No patients were receiving denosumab. Of enroled patients, 20/
37 (54.1%) had at least one SRE prior to study entry and 27 (76%,
61.9–89.5%) completed 12 weeks of study therapy. Ten patients did
not complete the 12 weeks of study, of these; 7 (70%) withdrew by
their own choice due to adverse events and 3 (30%) were with-
drawn by their physician due to disease progression.
3.2. Pain reduction
At baseline, patients rated their worst pain in the last 3 days
(measured by BPI-worst) as a median score of 2 (range¼0–9), witha mean (SD) FACT-BP of 47.2 (12.7). For those patients who had
pain scores at baseline and each of various time points, there were
no signiﬁcant changes in either FACT-BP or BPI-worst from base-
line to any on-study time point (Table 2). At week 12, the mean
(SD) change from baseline in FACT-BP was 1.22 (8.52) and in BPI-
worst was 0.16 (2.36), with p-values of 0.48 and 0.74
respectively.
Five patients had a complete pain response (though 4 of these
5 scored a 0 on their BPI-worst at baseline and were taking no
analgesics at baseline), 5 patients had a partial pain response, and
Table 2
Change of FACT-BP and BPI from baseline.
Time point N Mean (SD)
subscale score
Mean (SD)
change from
baseline
P-value N (%) who had an improvement in
subscale score of 4¼10% over
baseline (FACTBP)
N (%) who had 2 or
more increase in
BPI-worst
N (%) who had 2 or
more decrease in
BPI-worst
FACT-BP subscale 1 (Baseline) 35 46.64 (12.90) – – –
2 35 47.66 (11.44) 0.14 (5.36) 0.88 7(21.2%)
3 31 48.03 (9.56) 0.67 (5.86) 0.54 6 (20.7%)
4 27 47.04 (10.06) 1.22 (8.52) 0.48 6 (24.0%)
BPI-worst 1 (Baseline) 33 2.64 (2.66) – – – –
2 34 2.65 (2.44) 0.06 (1.46) 0.81 6 (18.8%) 2 (6.3%)
3 32 2.63 (2.18) 0.03 (2.64) 0.94 6 (20.7%) 5 (17.2%)
4 28 2.86 (2.22) -0.16 (2.36) 0.74 6 (24.0%) 6 (24.0%)
BPI-average 1 (Baseline) 33 1.61 (1.77) – – – –
2 34 1.65 (2.09) 0.03 (1.31) 0.89 2 (6.3%) 2 (6.3%)
3 31 1.55 (1.43) -0.07 (1.44) 0.80 2 (6.9%) 2 (6.9%)
4 28 1.75 (1.32) -0.08 (1.61) 0.81 2 (8.0%) 3 (12.0%)
BPI-now 1 (Baseline) 33 1.33 (2.03) – – – –
2 34 1.26 (1.96) -0.19 (1.57) 0.51 2 (6.3%) 1 (3.1%)
3 32 1.03 (1.20) -0.38 (1.80) 0.27 2 (6.9%) 5 (17.2%)
4 28 1.54 (1.88) -0.28 (1.81) 0.45 2 (8.0%) 2 (8.0%)
BPI-interference 1 (Baseline) 33 5.58 (5.95) – – – –
2 34 5.56 (6.13) -0.09 (3.79) 0.89 8 (25.0%) 6 (18.8%)
3 32 5.16 (4.36) -0.41 (5.32) 0.68 11 (37.9%) 8 (27.6%)
4 28 6.11 (5.07) -0.56 (4.92) 0.57 7 (28.0%) 7 (28.0%)
Table 4
Adverse event data.
Adverse event (AE)a Number (%) of patients having adverse events
AE grade1 AE grade2 AE gradeZ3 Total
Nausea 1 (2.7%) 14 (37.8%) 1 (2.7%) 16 (43.2%)
Vomiting 0 (0%) 6 (16.2%) 1 (2.7%) 7 (18.9%)
Fatigue 0 (0%) 6 (16.2%) 0 (0%) 6 (16.2%)
Diarrhoea 0 (0%) 4 (10.8%) 1 (2.7%) 5 (13.5%)
Headaches 0 (0%) 3 (8.1%) 0 (0%) 3 (8.1%)
Photosensitivity 0 (0%) 3 (8.1%) 0 (0%) 3 (8.1%)
Rash 0 (0%) 3 (8.1%) 0 (0%) 3 (8.1%)
Heartburn 0 (0%) 2 (5.4%) 0 (0%) 2 (5.4%)
Anorexia 0 (0%) 1 (2.7%) 0 (0%) 1 (2.7%)
Oral Mucositis 0 (0%) 1 (2.7%) 0 (0%) 1 (2.7%)
Malaise 0 (0%) 1 (2.7%) 0 (0%) 1 (2.7%)
Hypercalcaemia 0 (0%) 0 (0%) 0 (0%) 0 (0%)
a As deﬁned by the National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) Version 4.02.
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evaluated had withdrawn from the study, while four patients had
missing baseline measures. Considering these 12 patients as ‘fail-
ures to respond’, the overall pain response rate was 10/37 (27%,
95% CI¼14–44%). Only 3/37 (8%, 95% CI¼2% to 29%) of evaluable
patients had a pain response according to FACT-BP.
3.3. CTx and BSAP
Median baseline serum CTx for all patients was 140 ng/L (range
30–700 ng/L, Table 1). No signiﬁcant changes in CTx were observed
from baseline to any time point (see Table 3). By week 12, 29
patients had measured CTx and the median (1st and 3rd inter-
quartile) change was 24 (50, 73) (p-value¼0.23). Similarly, the
median (1st and 3rd interquartile) change from baseline in BSAP
was an increase of 0.3 (0.2, 1.3), which was not statistically
signiﬁcant (p¼0.18).
3.4. Toxicity
Toxicity was common, with 7 patients coming off study early
due to adverse events. Table 4 summarizes the main adverse event
data. Out of 37 patients 16 (43%) had GI adverse events (nausea,
vomiting and/or heartburn). The median (and range) of time from
starting doxycycline to development of GI toxicity was 9 (0–60)
days. The most common adverse events were nausea (n¼16 or
43.2%), vomiting (n¼7 or 18.9%), fatigue (n¼6 or 16.2%) andTable 3
Change of sCTx and BSAP from baseline.
Time point N Median (1st and
3rd interquartile)
Median (1st and 3rd
Interquartile) change
from baseline
p-value
sCTx 1 (Baseline) 37 140.0 (90.0, 310.0) – –
2 34 130.0 (85.0, 318.5) 9.5 (39, 46.5) 0.39
3 32 134.0 (88.8, 283.0) 21.5 (28.3, 59) 0.18
4 29 151.0 (81.0, 258.0) 24 (50, 73) 0.23
BSAP 1 (Baseline) 37 9.2 (7, 11.9) – –
2 33 9.4 (7.2, 12.2) 0.1 (1.6, 0.6) 0.93
3 32 8.4 (7.0, 13.1) 0.1 (0.9, 1.3) 0.91
4 29 8.9 (6.8, 11.9) 0.3 (0.2, 1.3) 0.18
BSAP¼Bone speciﬁc alkaline phosphatase μg/L; CTx¼serum C-telopeptide ng/L.diarrhoea (n¼5 or 13.5%). One grade 3 adverse event was ex-
perienced by each of 3 different patients (1 nausea, 1 vomiting and
1 diarrhoea).
Four patients had SREs (all palliative radiotherapy for painful
bone metastases) during the study.3.5. Bone marrow specimens
Of 37 patients, 36/37 (97%) completed a baseline biopsy and 25/
37 (68%) completed a week 12 bone biopsy. One baseline biopsy
was attempted but could not be completed (technical reasons).
Twelve patients (32%) did not complete the 12 week biopsy: 8 of
whom did not complete the 12 week study, 2 declined, and
2 biopsies were attempted but could not be completed (patient
body habitus). Of 36 baseline biopsies, 6 (17%) were positive for
metastatic carcinoma and Ki67 results were 42%, 4.1%, 16.9%,
32.6%, 11.4% and 14%. Of 25 week 12 biopsies, 3 were positive for
tumour cells and Ki67 results were 23%, 51% and 36.30%. Un-
fortunately, only one patient had paired results for baseline (Ki67
32.6%) and week 12 (36.30%).
Table 5
Prognostic factors for changes in FACT-BP and BPI-worst scores.
Outcome¼FACT-BP at 12 weeks Outcome¼BPI-Worst at 12 weeks
N Odds ratio (95% CI) p-value N Odds ratio (95% CI) p-value
Univariable analyses
Duration of bone mets (log) 36 0.90 (0.34, 2.38) 0.83 37 0.81 (0.31, 2.13) 0.67
PTH (log) 36 0.92 (0.23, 3.72) 0.91 37 1.28 (0.31, 5.33) 0.73
Vitamin D (log) 36 0.30 (0.03, 2.98) 0.31 37 0.95 (0.12, 7.72) 0.96
Month taking bisphosphonates (log) 36 1.51 (0.50, 4.51) 0.47 37 0.98 (0.36, 2.65) 0.96
Baseline CTx (log) 36 0.66 (0.25, 1.74) 0.40 37 0.41 (0.14, 1.17) 0.097
Baseline BSAP (log) 36 0.12 (0.02, 0.82) 0.031 37 0.15 (0.02, 0.93) 0.042
Number of prior SRE of any type 36 1.23 (0.82, 1.83) 0.32 37 1.05 (0.74, 1.48) 0.79
Baseline FACT-BP Subscale 33 0.96 (0.89, 1.04) 0.30 34 0.97 (0.90, 1.04) 0.42
Baseline BPI-severity (worst) 32 1.09 (0.79, 1.52) 0.59 33 1.08 (0.78, 1.50) 0.63
Multivariable analyses
Number of prior SRE of any type 30 2.35 (1.05, 5.25) 0.037 31 1.44 (0.90, 2.31) 0.131
Baseline BSAP (log) 0.01 (0.00, 0.37) 0.016 0.08 (0.01, 0.93) 0.044
Vitamin D (log) 0.05 (0.00, 2.99) 0.148 – –
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In univariate analyses, only baseline BSAP (log transformed)
was signiﬁcantly associated with completion of therapy (Table 5).
Patients with lower baseline BSAP were more likely to complete
treatment (Odds Ratio [OR]¼0.12, 95% conﬁdence interval [CI]¼
0.02–0.82, p-value¼0.031, on the log scale). Number of prior SRE
of any type (OR¼2.35, 95% CI¼1.05–5.25), baseline BSAP
(OR¼0.01, 95% CI¼0.00–0.37) and Vitamin D (OR¼0.05, 95%
CI¼0.00–2.99) all entered a multivariable regression model with
entry criteria of p¼0.15.
Baseline BSAP (log transformed) was univariately prognostic
for BPI-worst score at week 12 (Table 5). Lower baseline BSAP
were more likely to have response on BPI-worst at week 12
(OR¼0.15, 95%¼0.02–0.93, p¼0.042). It is notable that baseline
CTx approached statistical signiﬁcance (p¼0.097). Lower baseline
BSAP (log transformed) (OR¼0.08, 95% CI¼0.01–0.93) and in-
creased number of prior SRE of any type (OR¼1.44, 95% CI¼0.90–
2.31) were both prognostic for increased likelihood of response on
BPI-worst in the multivariable model.4. Discussion
Inhibitors of osteoclast function such as bisphosphonates and
denosumab are widely used in the care of patients with metastatic
bone disease. However, despite preclinical studies showing that
bisphosphonates have both direct [23] and indirect anti-tumour
[23], clinical studies have not demonstrated any discernable ef-
fects of bisphosphonates on either response, progression free or
overall survival [24]. We speculated that there are likely other
pathways that could be blocked to enhance the efﬁcacy of BTA
therapies both in the metastatic and adjuvant settings.
Based on previous preclinical studies suggesting that treatment
with the osteotropic antibiotic doxycycline resulted in increased
inhibition of tumour burden and increased bone formation when
combined with zoledronate [8], clinical studies assessing its efﬁ-
cacy in combination with BTAs were initiated. However, these
studies in cancer patients are distinct from the established role of
doxycycline (100 mg PO BID) as an antibiotic in the management
of rare types of lymphoma [25]. A completed Phase 1 trial of 14
patients with a range of advanced cancers assessed the safety and
pharmacology of doxycycline and conﬁrmed drug safety. [26]
While no objective responses were observed in this heavily pre-
treated cancer population, doxycycline concentrations reached
steady state levels by day 8. With mean trough levels of 420 μM,
the authors felt these concentrations were comparable to thoserequired for in vitro anti-tumour activity [6]. A subsequent study
in 12 breast cancer patients with newly diagnosed bone metas-
tases prior to commencement of bisphosphonate therapy used the
urinary N-telopeptide (uNTx) bone turnover marker to assess the
effects of doxycycline (100 mg PO BID) over a 3 month period [9].
There were no pathological fracture or hypercalcaemia events,
serum PTHrP levels (used in this study as a biomarker of tumour
growth) declined or remained stable after 12 weeks of therapy in
9/12 patients. Urinary NTx fell in half of the patients and the
magnitude of this fall (deﬁned as a 50% relative fall compared to
baseline) failed to satisfy the pre-speciﬁed outcome measure.
Study results suggested that not only does doxycycline (single
agent) have positive effects on bone turnover markers but also
that this dose appeared to be well tolerated in breast cancer pa-
tients with bone metastases. Unfortunately this study is only
presented in abstract form and no data is available to evaluate
whether these changes in NTx could actually have been due to
patients starting anti-cancer therapy [9].
Based on these previous ﬁndings and data supporting en-
hanced anti-tumour activity of doxycycline in combination with
zoledronate in preclinical models, our study hypothesised that for
women with bone metastases from breast cancer the addition of
doxycycline to their standard BTA therapy would result in sig-
niﬁcant palliative beneﬁts by preventing bone turnover and tu-
mour progression. Unfortunately, despite using similar doses to
those used in previous studies, no signiﬁcant effects on pain, or
markers of bone breakdown (i.e. sCTX) or bone formation (i.e.
BSAP) were seen. In contrast to the previous study in bispho-
sphonate-naïve breast cancer patients, our study only enroled
patients previously treated with bisphosphonates. The reason we
required that patients must have received their prior bispho-
sphonate therapy for at least 3 months was based on previous
studies that have shown that in most patients this is the time
required for the maximum fall and stabilisation of bone turnover
markers such as CTx and NTx [15,22]. If we had entered patients
on study sooner we would not have been aware of whether or not
any fall in biomarker levels was due to the bisphosphonate or the
doxycycline. Similarly we have also demonstrated previously that
a change in anti-cancer agent therapy can also cause a fall in bone
biomarkers [16,19]. So again patients could not have a change in
anti-cancer therapy for 4 weeks prior to study entry or anticipated
changes in the 4 weeks after entering the study. Similarly one
would not have anticipated that bone turnover markers would
begin to fall after a minimum of 12 weeks of therapy, hence this
time point was chosen for the duration of the study as it has been
shown to be robust time point in previous studies [21,27]. As such
it is possible that previous bisphosphonate treatment alters the
C.L. Addison et al. / Journal of Bone Oncology 5 (2016) 173–179178bone microenvironment sufﬁciently to impair the previously ob-
served anti-tumour effects of doxycycline.
The effects of this treatment on tumour cells was also assessed
by evaluation of bone marrow specimens. The proportion of
samples that contained identiﬁable tumour cells was quite low,
with tumour cells being seen in only 17% of baseline bone marrow
specimens and 12% of the week 12 specimens. Only one patient
had tumour cells in paired specimens precluding meaningful
proposed analyses pre and post-doxycycline treatment to assess
effects on tumour growth.
Toxicity was signiﬁcant and limiting in this patient population.
Drug toxicity was by far the most common reason for patients
failing to complete treatment. Out of 37 patients, 16 (43%) had GI
adverse events (nausea, vomiting and/or heartburn), and this be-
came limiting for 7 of these patients requiring them to come off
study early. Once GI toxicity started it was our clinical impression
that it persisted despite lowering the dose of doxycycline. As part
of an ad hoc analysis we decided to evaluate the time to devel-
opment of GI toxicity. The median (and range) of time from
starting the doxycycline to development of GI toxicity was 9 (0–
60) days, this means that potential future studies evaluating this
agent would be signiﬁcantly limited in this patient population.
An important questions remain as to why the clinical results
have not replicated the preclinical data. This can likely be divided
into a few key components. First, the fundamental limitations of
animal models in bone metastasis research, the second reﬂecting
the limitations of the preclinical research with doxycycline and
ﬁnally the realities of studies performed in humans. With respect
to animal models of bone metastasis behaviour our group and
others have reported that preclinical models frequently do not
reﬂect the presence of pre-existing bone metastases and their
treatment [28]. For example, the preclinical data for the current
study was developed in a breast cancer model of bone metastasis
using xenografts used doxycycline releasing pellets implanted
subcutaneously in animals 3 days prior to seeding of the bone with
breast tumour cells (MDA-MB-231) via intracardiac injections with
zoledronic acid injections every 2 days thereafter [8]. The release
of doxycycline 3 days prior to seeding of the bone with tumour
cells in the preclinical model, may have resulted in modiﬁcations
of the bone microenvironment that delayed tumour initiation and
growth resulting in the observed therapeutic effect at endpoint.
This perhaps better reﬂect effects of this combination treatment
on prevention of bone metastasis or inhibition of early dis-
seminated micrometastases as opposed to therapeutic effects on
advanced bone metastases as would be the case for the patients
enroled in this study.
With respect to the realities of translating preclinical data into
studies in humans it is important to remember that animal model
are genetically homogeneity whereas patients are heterogeneous
with tumours that are also heterogeneous. Because of the well-
recognised effects of bisphosphonates on bone turn over markers
the clinical study required that patients have received at least
three months of bisphosphonate prior to commencing doxycy-
cline. It is possible that pretreatment with bisphosphonates could
result in different effects of doxycycline being observed, as many
drugs are known to have synergistic effects only if given sequen-
tially instead of concurrently or after the initial drug. As such is
remains possible that doxycycline delivered prior to bispho-
sphonates in the preclinical model sensitised bone metastases to
the bisphosphonates, however when given after bisphosphonates,
this effect is ameliorated. In addition, in the clinical study, all pa-
tients received pamidronate and not zoledronic acid. As zoledronic
acid has been shown to be superior to pamidronate in controlling
bone turnover in other clinical studies, it is possible that the re-
sults are driven by the lack of effect of doxycycline in combination
with pamidronate, which was not tested preclinically [22]. Finally,in the clinical trial patients were allowed to be on other con-
current anti-cancer therapies. The preclinical model did not use
any combinations with chemotherapy or endocrine therapy and in
fact supplemented with oestrogen releasing pellets (even though
breast cell line was triple negative). Although some evidence that
doxycycline can enhance efﬁcacy of chemotherapies such as cis-
platin [29] it is not clear whether or not anti-cancer therapies in
the patients could have altered the effects of doxycycline on the
bone.
Limitations include the use of surrogate markers of palliative
beneﬁt (i.e. pain scores and serum CTx) as co-primary endpoints.
Surrogate markers were needed as the sample size is too small for
radiological response to be a useful study endpoint. The limita-
tions of pain scores in patients with bone metastases are well
recognised [15,19,20,22]. For these reasons many studies of BTAs
in cancer patients with bone metastases also use biochemical
markers of bone turnover (i.e. uNTX, sCTX). These have been
previously correlated with; pain severity, response to treatment,
decrease in SREs and survival [30–32]. Similarly, a number of
groups are also evaluating the role of bone formation markers
such as P1NP (Procollagen type I amino-terminal propeptide) and
BSAP as biomarkers of BTA response [33]. Our group has con-
sistently shown that these markers of bone turnover and espe-
cially the serum c-telopeptide are rapid and valid surrogates for
assessing the palliative beneﬁts caused by changes in BTA thera-
pies [17,18]. However, they remain a surrogate and should only be
considered hypothesis generating.5. Conclusion
This is the largest study to date evaluating the effects of dox-
ycycline in bone-metastatic breast cancer patients. Doxycycline
daily for 12 weeks did not appear to signiﬁcantly enhance pallia-
tive beneﬁt nor change bone resorption markers. The toxicity
proﬁle of doxycycline in this patient population will make further
evaluation challenging.Conﬂicts of interest
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